Your Messages Inbox
Your Article Summary
See Latest ArticlesImmunoGen Announces Amgen has Licensed Rights to Use the Companys TAP Technology for a Solid Tumor Target
ImmunoGen, Inc., 09/17/09
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Payload technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09
Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09
PR distribution service for the biotech industry
b3c newswire, 12/07/09
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar mania
AstraZeneca, 12/07/09
Article Search
Sponsor